Clinical Trial Update: T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating a KRAS-targeted T cell receptor gene-engineered T cell therapy for patients with advanced solid tumors and is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KRAS-targeted TCR gene-engineered T cell therapy

Snippet

Sponsor: TingBo Liang | Conditions: Tumor, Solid | Phase 1 | Status: RECRUITING